AU2001288863A1 - Compositions and methods for inducing specific cytolytic t cell responses - Google Patents

Compositions and methods for inducing specific cytolytic t cell responses

Info

Publication number
AU2001288863A1
AU2001288863A1 AU2001288863A AU8886301A AU2001288863A1 AU 2001288863 A1 AU2001288863 A1 AU 2001288863A1 AU 2001288863 A AU2001288863 A AU 2001288863A AU 8886301 A AU8886301 A AU 8886301A AU 2001288863 A1 AU2001288863 A1 AU 2001288863A1
Authority
AU
Australia
Prior art keywords
aberrant cell
selective
pathologically aberrant
mixture
target antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288863A
Inventor
Rita Maccario
Daniela Montagna
Antonella Vitiello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of AU2001288863A1 publication Critical patent/AU2001288863A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)

Abstract

The invention provides a method of inducing CD8+ T lymphocytes selective for a pathologically aberrant cell ex vivo. The method consists of contacting an apoptotic pathologically aberrant cell with a mixture having at least dendritic cells (DC), CD4+ T cells and CD8+ T lymphocytes, and culturing an apoptotic pathologically aberrant cell with the mixture for sufficient time to generate CD8+ T lymphocytes (TL) having antigenic specificity for, and/or selective cytolytic activity toward a pathologically aberrant cell. The invention further provides a method of inducing CD8+ TL selective for one or more target antigens ex vivo. The method consists of contacting one or more target antigens with a mixture having at least dendritic cells (DC), CD4+ T cells, CD8+ TL and IL-7, and culturing said one or more target antigens with the mixture for sufficient time to generate CD8+ TL having selective immune reactivity toward one or more target antigens. The invention further provides a method of treating a patient having a disease mediated by a pathologically aberrant cell. The method consists of administering an effective amount of a CD8+ TL produced by the methods of the invention having antigenic specificity for, and/or selective cytolytic activity toward a pathologically aberrant cell.
AU2001288863A 2000-09-15 2001-09-06 Compositions and methods for inducing specific cytolytic t cell responses Abandoned AU2001288863A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23300900P 2000-09-15 2000-09-15
US60233009 2000-09-15
PCT/US2001/028016 WO2002022648A2 (en) 2000-09-15 2001-09-06 Compositions and methods for inducing specific cytolytic t cell responses

Publications (1)

Publication Number Publication Date
AU2001288863A1 true AU2001288863A1 (en) 2002-03-26

Family

ID=22875500

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288863A Abandoned AU2001288863A1 (en) 2000-09-15 2001-09-06 Compositions and methods for inducing specific cytolytic t cell responses

Country Status (12)

Country Link
US (1) US20020119121A1 (en)
EP (1) EP1326961B1 (en)
JP (1) JP2004512030A (en)
AT (1) ATE371017T1 (en)
AU (1) AU2001288863A1 (en)
CA (1) CA2422454A1 (en)
CY (1) CY1107802T1 (en)
DE (1) DE60130130T2 (en)
DK (1) DK1326961T3 (en)
ES (1) ES2292619T3 (en)
PT (1) PT1326961E (en)
WO (1) WO2002022648A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
EP1434596B1 (en) * 2001-10-09 2009-07-08 Mayo Foundation For Medical Education And Research Enhancement of immune responses by agonist 4-1bb-antibodies
US20040115216A1 (en) * 2002-07-12 2004-06-17 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
CN1846000B (en) 2003-09-05 2012-10-03 金克克国际有限公司 HPV CD8+ T-cell epitopes
US20080199484A1 (en) * 2003-10-06 2008-08-21 Cedars-Sinai Medical Center Use Of Cox-2 Inhibitor to Prevent T-Cell Anergy Induced By Dendritic Cell Therapy
EP1676132B1 (en) * 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
JP2008521406A (en) 2004-11-24 2008-06-26 フレッド ハッチンソン キャンサー リサーチ センター Use of IL-21 for adoptive immunotherapy and identification of tumor antigens
US7745209B2 (en) 2005-07-26 2010-06-29 Corning Incorporated Multilayered cell culture apparatus
ITMI20052018A1 (en) * 2005-10-21 2007-04-22 Univ Bari CELLULAR LINE OF RENAL CARCINOMA AND ITS USE
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
EP2084267B1 (en) * 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8097256B2 (en) * 2006-09-28 2012-01-17 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
AU2007307206B2 (en) 2006-10-04 2016-02-11 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
CA2671967A1 (en) 2006-12-07 2008-06-19 Wilson Wolf Manufacturing Corporation Highly efficient devices and methods for culturing cells
AR060424A1 (en) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec CELLULAR LINES, COMPOSITIONS FOR THE TREATMENT OF MELANOMS THAT UNDERSTAND PROCEDURES TO PREPARE COMPOSITIONS AND TREATMENT METHODS
ES2565779T3 (en) * 2008-09-02 2016-04-06 Cedars-Sinai Medical Center CD133 epitopes
ES2342529B1 (en) * 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. ONCOSTATINA M AS POTENTIATOR OF THE IMMUNOSTIMULATING ACTIVITY OF HUMAN EPITHELIAL CELLS.
PL2427485T3 (en) 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Cd133 epitopes
WO2010151517A2 (en) * 2009-06-25 2010-12-29 The Regents Of The University Of Michigan Antigen-specific long-term memory t-cells
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
WO2011060205A1 (en) * 2009-11-11 2011-05-19 The Trustees Of Columbia University In The City Of New York Methods, compositions, and assays for determining the effect of an immune cell on a cell from an infectious or neoplastic disease
AU2012351347B2 (en) 2011-12-12 2016-05-19 Baylor College Of Medicine Process of expanding T cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (en) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes to generate multiviral ctls with broad specificity
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3052131B1 (en) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
US10627411B2 (en) * 2014-03-27 2020-04-21 British Columbia Cancer Agency Branch T-cell epitope identification
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
EP3171896A4 (en) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Targeting dna-pkcs and b7-h1 to treat cancer
CN113943703A (en) 2015-09-18 2022-01-18 贝勒医学院 Identification of immunogenic antigens from pathogens and correlation with clinical efficacy
CN114231486A (en) 2015-10-30 2022-03-25 儿童国家医疗中心 Generation of HPV antigen-specific T cells from naive T cell populations
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
US9642906B2 (en) 2016-09-16 2017-05-09 Baylor College Of Medicine Generation of HPV-specific T-cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
US6602709B1 (en) * 1998-02-20 2003-08-05 The Rockefeller University Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes

Also Published As

Publication number Publication date
DE60130130T2 (en) 2008-05-15
US20020119121A1 (en) 2002-08-29
CY1107802T1 (en) 2013-06-19
JP2004512030A (en) 2004-04-22
ATE371017T1 (en) 2007-09-15
DE60130130D1 (en) 2007-10-04
WO2002022648A2 (en) 2002-03-21
PT1326961E (en) 2007-10-02
EP1326961B1 (en) 2007-08-22
WO2002022648A3 (en) 2002-05-30
ES2292619T3 (en) 2008-03-16
EP1326961A4 (en) 2005-11-09
EP1326961A2 (en) 2003-07-16
DK1326961T3 (en) 2008-01-07
CA2422454A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AU2001288863A1 (en) Compositions and methods for inducing specific cytolytic t cell responses
Mason et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy
McEwen-Smith et al. The regulatory role of invariant NKT cells in tumor immunity
Charmoy et al. Neutrophil-derived CCL3 is essential for the rapid recruitment of dendritic cells to the site of Leishmania major inoculation in resistant mice
Belyakov et al. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells
York et al. Immune regulatory CNS-reactive CD8+ T cells in experimental autoimmune encephalomyelitis
HUP9904697A2 (en) Methods and compositions for immunomodulation
GB2384709B (en) Compositions for stimulating a CD4+ T cell response for use in a prime boost vaccination method
Rothe et al. Interleukin-12 gene expression is associated with rapid development of diabetes mellitus in non-obese diabetic mice
WO1999042564A3 (en) Apoptotic cell-mediated antigen presentation to dendritic cells
NO20050447L (en) Isolation and identification of T cells
Waldowska et al. A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies
WO1998033527A3 (en) Cancer immunotherapy with semi-allogeneic cells
Frimpong-Boateng et al. Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFβ
Rocco et al. Regulatory T cells: the ultimate HIV reservoir?
Rubio et al. Mechanisms of the antitumor responses and host-versus-graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: a critical role for recipient CD4+ T cells and recipient leukocyte infusion-derived IFN-γ-producing CD8+ T cells
Sireci et al. Patterns of phosphoantigen stimulation of human Vγ9/Vδ2 T cell clones include Th0 cytokines
Londei et al. Efficient Propagation and Cloning of Human T Cells in the Absence of Antigen by Means of OKT3, Interleukin 2, and Antigen‐Presenting Cells
GB2355983B (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
Ishii et al. A combination of check-point blockade and α-galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo
Xiao-wen et al. Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting
Kurihara et al. Potential immunogenicity of adult T cell leukemia cells in vivo
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
Berzofsky A push–pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses
IL189615A0 (en) Melanoma vaccine and methods of making and using same